New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs
June 20 2017 - 9:30AM
Data Presented at
EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive
EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved
Device Longevity
DUBLIN and VIENNA - June 20, 2017
- Medtronic plc (NSYE: MDT) today announced new data showing
that use of its cardiac resynchronization therapy (CRT) devices -
with its proprietary AdaptivCRT(TM) and EffectiveCRT(TM) algorithms
- results in lower healthcare system costs, and improves therapy
delivery in heart failure patients who also have atrial
fibrillation (AF). The results of three analyses were presented at
the EHRA EUROPACE-CARDIOSTIM 2017 in Vienna.
Findings from a European health-economic analysis
demonstrated that treating patients with AdaptivCRT results in
lower healthcare costs and extends life expectancy by an average of
four months. The findings, which span three countries' healthcare
systems, showed that lifetime costs for patients treated with
AdaptivCRT were lower than for patients treated with traditional
pacing algorithms:
|
With AdaptivCRT algorithm |
Without AdaptivCRT algorithm |
Italy |
€28,113.00 |
€29,215.16 |
Spain |
€29,618.89 |
€30,833.93 |
United Kingdom |
€29,425.37 (£25,454.47) |
€30,273.19 (£26,274.39) |
The AdaptivCRT algorithm is available in the
Medtronic Claria MRI(TM) Quad CRT-D SureScan(TM), Amplia MRI(TM)
Quad CRT-D SureScan(TM), Percepta(TM) Quad CRT-P MRI SureScan(TM)
and Serena(TM) Quad CRT-P MRI SureScan(TM) systems. It adjusts the
way the device paces the heart according to minute-to-minute
evaluations of each patient's rhythm, and leads to improved
outcomes through reducing patients' odds of a 30-day heart failure
readmission1 and their
risk of developing AF2.
A second analysis - from the prospective,
randomized CRTee study - showed that the Medtronic device-based
EffectivCRT during AF algorithm improved effective left ventricular
pacing by 19 percent (87±16 percent vs. 68 ± 37 percent;
p<0.001) in patients with AF, compared to devices without the
technology.
"It is exciting to see that this technology helps
increase the amount of CRT delivered during atrial fibrillation,"
said Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at
the University of Modena and Reggio Emilia, Italy. "Many patients
with heart failure experience AF at some point, and we now have the
ability to better address the individual needs of these
difficult-to-treat patients."
AF is one of the most common heart rhythm
disorders. It involves an irregular quivering or rapid rhythm in
the heart's upper chambers. A large percentage of heart failure
patients receiving CRT also have AF3, which can
significantly reduce patient response to the therapy. The
EffectivCRT Diagnostic, exclusive to the Medtronic Claria CRT-D and
Percepta CRT-P devices, automatically determines the effectiveness
of left ventricular pacing, and the EffectivCRT during AF algorithm
automatically adjusts pacing rates during AF.
"These analyses reinforce Medtronic's leadership
in providing treatments and solutions that not only improve patient
outcomes and CRT delivery, but also dramatically reduce healthcare
utilization," said Kweli P. Thompson, M.D., M.P.H., vice president
and general manager of the CRT business, which is part of the
Cardiac and Vascular Group at Medtronic. "Beyond the clinical
benefits of the AdaptivCRT and EffectivCRT algorithms, our newest
devices with these features also demonstrate improved
longevity."
Finally, the latest economic analysis of Medtronic
CRT-defibrillators (CRT-D) demonstrated a highly significant
increase in projected device longevity: up to nine (9) years for
Claria and Amplia devices, and 8.1 years in Viva XT(TM) CRT-Ds,
which are substantial improvements compared to predecessor
models.
"By improving device longevity, there are
substantially fewer device replacements and, in turn, significant
cost savings and fewer procedure-related complications," said Haran
Burri, M.D., Ph.D., associate professor of cardiology at the
University Hospital of Geneva, Switzerland.
In collaboration with leading clinicians,
researchers and scientists worldwide, Medtronic offers the broadest
range of innovative medical technology for the interventional and
surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of
the highest quality that deliver clinical and economic value to
healthcare consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Starling
RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization
Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT
Trial. JACC Heart Fail. July 2015;3(7):565-572.
2 Martin
D, et al. Clinical outcomes with adaptive cardiac resynchronization
therapy: Long-term outcomes of the Adaptive CRT Trial. HFSA Annual
Scientific Meeting. September 23, 2013.
3 Kloosterman
M, Maass AH, Rienstra M, Van Gelder IC. Atrial fibrillation during
cardiac resynchronization therapy. Card Electrophysiol Clin.
December 2015;7(4):735-748.
Contacts:
Tracy McNulty
Public Relations
+1-763-526-2492
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024